Other names: GPP; Pustular Psoriasis

Generalized pustular psoriasis (GPP) is a rare and extreme form of psoriasis.

GPP is characterized by repeated episodes in which large areas of skin become red and inflamed and develop small pus-filled blisters (pustules). It is caused by neutrophils (a type of white blood cell) accumulating in the skin.

The skin problems can be accompanied by fever, extreme tiredness, muscle weakness, an increased number of white blood cells, and other signs of inflammation throughout the body.

Episodes can be triggered by infection, exposure to or withdrawal from certain medications, menstruation, or pregnancy, although the trigger is often unknown. GPP can be life-threatening if not treated.

Spevigo (spesolimab-sbzo) is the first FDA-approved treatment option for generalized pustular psoriasis. It works by blocking the activation of the interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.

Drugs used to treat Generalized Pustular Psoriasis